Dr Lenka Munoz

Senior Lecturer
Pathology, School of Medical Sciences

Telephone +61 2 9351 2315
Fax +61 2 9351 3868

Map

Research interests

Dr Munoz research focuses on understanding the signal transduction mechanisms that cause inflammatory and malignant diseases, and on deriving new approaches to disease treatment.

Current projects

Undergraduate, Honours and postgraduate research projects are available and would focus on one of major research programs in our laboratory.

1. Role of MK2 in glioblastoma chemoresistance.

2. Function of DYRK1A in brain cancer.

3. Off-kinase targets and novel molecular mechanisms of kinase inhibitors.

Please contact me directly for more details.

Selected grants

2015

  • Preparative High-Performance Liquid Chromatograph (Preparative-HPLC) for Expediting Drug Translation; Codd R, Payne R, Kassiou M, Groundwater P, Munoz L; DVC Research/Equipment Grant.
  • SMSF Grant 2015 Munoz; Munoz L; Sydney Medical School/Research Support.

2013

  • Improving chemotherapy response rates in brain cancer; Munoz L; Sydney Foundation for Medical Research/Research Support.
  • Development of small molecule inhibitors of LRRK2 for treatment of Parkinsons disease; Kassiou M, Munoz L; Parkinson's New South Wales Incorporated/Research Support.
  • A novel approach to overcome chemotherapy resistance in glioblastoma; Munoz L; DVC Research/Brown Fellowships.

2009

  • Integrating chemistry and biology in the search for new therapeutics for Alzheimer's disease; Munoz L; The Judith Jane Mason and Harold Stannett Williams Memorial Foundation/Medical and Scientific Research Grants.
  • Integrating Chemistry and Biology in the Search for New Therapeutics for Alzheimer's disease; Munoz L, Ammit A, Guillemin G, Guillemin G; Alzheimer’s Australia Dementia Research Foundation/Dementia Grants Program.

2008

  • Targeting inactive p38alpha kinase as a strategy to treat rheumatoid arthritis; Munoz L; Arthritis Foundation of Australia/Research Support.
  • Discovery of novel drugs to treat alzheimers disease; Munoz L; Rebecca L Cooper Medical Research Foundation/Research Support.
  • Targeting inactive p38a MAPK as a novel strategy to treat neurodegenerative disorders; Munoz L, Peifer C; Deutscher Akademischer Austausch Dienst (DAAD)/Travelling Fellowship.
  • Will Selective p38 MAPK Inhibitor Prevent Brain Tumour Progression and Metastasis; Munoz L; Cure for Life Foundation/Research Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Vinh, N., Devine, S., Munoz, L., Ryan, R., Wang, B., Krum, H., Chalmers, D., Simpson, J., Scammells, P. (2015). Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK. ChemistryOpen, 4(1), 56-64. [More Information]
  • Munoz, L., Kavanagh, M., Phoa, A., Heng, B., Dzamko, N., Chen, E., Doddareddy, M., Guillemin, G., Kassiou, M. (2015). Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 95, 29-34. [More Information]
  • Gurgis, F., Yeung, Y., Tang, M., Heng, B., Buckland, M., Ammit, A., Haapasalo, J., Haapasalo, H., Guillemin, G., Grewal, T., Munoz, L. (2015). The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells. Oncogene, 34(22), 2934-2942. [More Information]
  • Gurgis, F., Ziaziaris, W., Munoz, L. (2014). Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation and Cell Cycle: Role and Targeting. Molecular Pharmacology, 85(2), 345-356. [More Information]
  • Yeung, Y., McDonald, K., Grewal, T., Munoz, L. (2013). Interleukins in glioblastoma pathophysiology: implications for therapy. British Journal of Pharmacology, 168(3), 591-606. [More Information]
  • Eibl, C., Tomassoli, I., Munoz, L., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. Bioorganic and Medicinal Chemistry, 21(23), 7283-7308. [More Information]
  • Eibl, C., Munoz, L., Tomassoli, I., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicylo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. Bioorganic and Medicinal Chemistry, 21(23), 7309-7329. [More Information]
  • Yeung, Y., Bryce, N., Adams, S., Braidy, N., Konayagi, M., McDonald, K., Teo, C., Guillemin, G., Grewal, T., Munoz, L. (2012). p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. Journal of Neuro-Oncology, 109(1), 35-44. [More Information]
  • Munoz, L., Selig, R., Yeung, Y., Peifer, C., Hauser, D., Laufer, S. (2010). Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. Analytical Biochemistry, 401(1), 125-133. [More Information]
  • Munoz, L., Ramsay, E., Manetsch, M., Ge, Q., Peifer, C., Laufer, S., Ammit, A. (2010). Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European Journal of Pharmacology, 635, 212-218. [More Information]
  • Munoz, L., Ammit, A. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology, 58(3), 561-568. [More Information]
  • Munoz, L., Ranaivo, H., Roy, S., Hu, W., Craft, J., McNamara, L., Chico, L., Van Eldik, L., Watterson, D. (2007). A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation, 4(21), Published online 2007 September 4. doi: 10.1186/17.
  • Hu, W., Ranaivo, H., Roy, S., Behanna, H., Wing, L., Munoz, L., Guo, L., Van Eldik, L., Watterson, D. (2007). Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(2), 414-418. [More Information]
  • Gundisch, D., Andrä, M., Munoz, L., Tilotta, M. (2004). Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 12, 4953-4962. [More Information]
  • Munoz, L., Laitinen, L., Raiman, J., Cizmarik, J., Sedlárová, E., Hirvonen, J. (2002). Permeability Profiles of M-Alkoxysubstituted Pyrrolidinoethylesters of Phenylcarbamic Acid across Caco-2 Monolayers and Human Skin. Pharmaceutical Research, 19(2), 162-168.
  • Munoz, L., Sedlárová, E., Cizmarik, J. (2002). Study of Local Anaesthetics, Part 156: Some Physicochemical and Lipophilic Properties of Pyrrolidinoethyl Esters of o-, m-, p-Alkoxy-Substituted Phenylcarbamic Acid. Chemical Papers, 56(5), 340-344.

2015

  • Vinh, N., Devine, S., Munoz, L., Ryan, R., Wang, B., Krum, H., Chalmers, D., Simpson, J., Scammells, P. (2015). Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK. ChemistryOpen, 4(1), 56-64. [More Information]
  • Munoz, L., Kavanagh, M., Phoa, A., Heng, B., Dzamko, N., Chen, E., Doddareddy, M., Guillemin, G., Kassiou, M. (2015). Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 95, 29-34. [More Information]
  • Gurgis, F., Yeung, Y., Tang, M., Heng, B., Buckland, M., Ammit, A., Haapasalo, J., Haapasalo, H., Guillemin, G., Grewal, T., Munoz, L. (2015). The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells. Oncogene, 34(22), 2934-2942. [More Information]

2014

  • Gurgis, F., Ziaziaris, W., Munoz, L. (2014). Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation and Cell Cycle: Role and Targeting. Molecular Pharmacology, 85(2), 345-356. [More Information]

2013

  • Yeung, Y., McDonald, K., Grewal, T., Munoz, L. (2013). Interleukins in glioblastoma pathophysiology: implications for therapy. British Journal of Pharmacology, 168(3), 591-606. [More Information]
  • Eibl, C., Tomassoli, I., Munoz, L., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. Bioorganic and Medicinal Chemistry, 21(23), 7283-7308. [More Information]
  • Eibl, C., Munoz, L., Tomassoli, I., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicylo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. Bioorganic and Medicinal Chemistry, 21(23), 7309-7329. [More Information]

2012

  • Yeung, Y., Bryce, N., Adams, S., Braidy, N., Konayagi, M., McDonald, K., Teo, C., Guillemin, G., Grewal, T., Munoz, L. (2012). p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. Journal of Neuro-Oncology, 109(1), 35-44. [More Information]

2010

  • Munoz, L., Selig, R., Yeung, Y., Peifer, C., Hauser, D., Laufer, S. (2010). Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. Analytical Biochemistry, 401(1), 125-133. [More Information]
  • Munoz, L., Ramsay, E., Manetsch, M., Ge, Q., Peifer, C., Laufer, S., Ammit, A. (2010). Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European Journal of Pharmacology, 635, 212-218. [More Information]
  • Munoz, L., Ammit, A. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology, 58(3), 561-568. [More Information]

2007

  • Munoz, L., Ranaivo, H., Roy, S., Hu, W., Craft, J., McNamara, L., Chico, L., Van Eldik, L., Watterson, D. (2007). A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation, 4(21), Published online 2007 September 4. doi: 10.1186/17.
  • Hu, W., Ranaivo, H., Roy, S., Behanna, H., Wing, L., Munoz, L., Guo, L., Van Eldik, L., Watterson, D. (2007). Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(2), 414-418. [More Information]

2004

  • Gundisch, D., Andrä, M., Munoz, L., Tilotta, M. (2004). Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 12, 4953-4962. [More Information]

2002

  • Munoz, L., Laitinen, L., Raiman, J., Cizmarik, J., Sedlárová, E., Hirvonen, J. (2002). Permeability Profiles of M-Alkoxysubstituted Pyrrolidinoethylesters of Phenylcarbamic Acid across Caco-2 Monolayers and Human Skin. Pharmaceutical Research, 19(2), 162-168.
  • Munoz, L., Sedlárová, E., Cizmarik, J. (2002). Study of Local Anaesthetics, Part 156: Some Physicochemical and Lipophilic Properties of Pyrrolidinoethyl Esters of o-, m-, p-Alkoxy-Substituted Phenylcarbamic Acid. Chemical Papers, 56(5), 340-344.

To update your profile click here. For support on your academic profile contact .